The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 07, 2014

Filed:

Nov. 30, 2010
Applicants:

Frank Osterroth, Dietzenbach, DE;

Christoph Uherek, Seligenstadt, DE;

Christoph Bruecher, Eschborn, DE;

Peter Röttgen, Ladenburg, DE;

Benjamin Daelken, Frankfurt am Main, DE;

André Engling, Bad Homburg, DE;

Chantal Zuber, Frankfurt am Main, DE;

Niklas Czeloth, Dreieich, DE;

Andrea Wartenberg-demand, Schrecksbach, DE;

Marcus Gutscher, Langen, DE;

Judith Wessels-kranz, Frankfurt am Main, DE;

Inventors:

Frank Osterroth, Dietzenbach, DE;

Christoph Uherek, Seligenstadt, DE;

Christoph Bruecher, Eschborn, DE;

Peter Röttgen, Ladenburg, DE;

Benjamin Daelken, Frankfurt am Main, DE;

André Engling, Bad Homburg, DE;

Chantal Zuber, Frankfurt am Main, DE;

Niklas Czeloth, Dreieich, DE;

Andrea Wartenberg-Demand, Schrecksbach, DE;

Marcus Gutscher, Langen, DE;

Judith Wessels-Kranz, Frankfurt am Main, DE;

Assignee:

Biotest AG, Dreieich, DE;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/53 (2006.01); G01N 33/577 (2006.01); G01N 33/58 (2006.01); C07K 16/00 (2006.01); C07K 16/24 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/244 (2013.01); C07K 2299/00 (2013.01); C07K 2317/55 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); A61K 2039/505 (2013.01); C07K 2317/92 (2013.01);
Abstract

Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (Th-10), wherein said antibody or fragment thereof is capable of being administered to a subject in the absence of an intolerable increase in the level of pro-inflammatory cytokines. Further provided are methods of treatment involving the use of the antibody or fragment thereof.


Find Patent Forward Citations

Loading…